http://purl.org/np/RAo2_Vl7BPtEMnusRlyv7yq5u48JfxgHZdFwWHFxLtJr4#Head http://purl.org/np/RAo2_Vl7BPtEMnusRlyv7yq5u48JfxgHZdFwWHFxLtJr4 http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RAo2_Vl7BPtEMnusRlyv7yq5u48JfxgHZdFwWHFxLtJr4#assertion http://purl.org/np/RAo2_Vl7BPtEMnusRlyv7yq5u48JfxgHZdFwWHFxLtJr4 http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RAo2_Vl7BPtEMnusRlyv7yq5u48JfxgHZdFwWHFxLtJr4#provenance http://purl.org/np/RAo2_Vl7BPtEMnusRlyv7yq5u48JfxgHZdFwWHFxLtJr4 http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RAo2_Vl7BPtEMnusRlyv7yq5u48JfxgHZdFwWHFxLtJr4#pubinfo http://purl.org/np/RAo2_Vl7BPtEMnusRlyv7yq5u48JfxgHZdFwWHFxLtJr4 http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RAo2_Vl7BPtEMnusRlyv7yq5u48JfxgHZdFwWHFxLtJr4#assertion http://purl.obolibrary.org/obo/DOID_6132 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RAo2_Vl7BPtEMnusRlyv7yq5u48JfxgHZdFwWHFxLtJr4#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_6132 http://purl.org/np/RAo2_Vl7BPtEMnusRlyv7yq5u48JfxgHZdFwWHFxLtJr4#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RAo2_Vl7BPtEMnusRlyv7yq5u48JfxgHZdFwWHFxLtJr4#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB00671 http://purl.org/np/RAo2_Vl7BPtEMnusRlyv7yq5u48JfxgHZdFwWHFxLtJr4#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RAo2_Vl7BPtEMnusRlyv7yq5u48JfxgHZdFwWHFxLtJr4#association http://www.w3.org/2000/01/rdf-schema#label cefixime is a cephalosporin antibacterial drug indicated in the treatment of adults and pediatric patients six months and older with the following infections uncomplicated urinary tract infections 1 1 otitis media 1 2 pharyngitis and tonsillitis 1 3 acute exacerbations of chronic bronchitis 1 4 uncomplicated gonorrhea cervical urethral 1 5 to reduce the development of drug resistant bacteria and maintain the effectiveness of cefixime and other antibacterial drugs cefixime for oral suspension and cefixime capsules should be used only to treat infections that are proven or strongly suspected to be caused by bacteria 1 6 cefixime for oral suspension and cefixime capsule is indicated in the treatment of adults and pediatric patients six months of age or older with uncomplicated urinary tract infections caused by susceptible isolates of escherichia coli proteus mirabilis cefixime for oral suspension and cefixime capsule is indicated in the treatment of adults and pediatric patients six months of age or older with otitis media caused by susceptible isolates of haemophilus influenzae moraxella catarrhalis streptococcus pyogenes streptococcus pyogenes note for patients with otitis media caused by streptococcus pneumoniae see clinical studies 14 cefixime for oral suspension and cefixime capsule is indicated in the treatment of adults and pediatric patients six months of age or older with pharyngitis and tonsillitis caused by susceptible isolates of streptococcus pyogenes note penicillin is the usual drug of choice in the treatment of streptococcus pyogenes infections cefixime for oral suspension and cefixime capsule is generally effective in the eradication of streptococcus pyogenes from the nasopharynx however data establishing the efficacy of cefixime for oral suspension and cefixime capsule in the subsequent prevention of rheumatic fever is not available cefixime for oral suspension and cefixime capsule is indicated in the treatment of adults and pediatric patients six months of age or older with acute exacerbations of chronic bronchitis caused by susceptible isolates of streptococcus pneumoniae haemophilus influenzae cefixime for oral suspension and cefixime capsule is indicated in the treatment of adults and pediatric patients six months of age or older with uncomplicated gonorrhea cervical urethral caused by susceptible isolates of neisseria gonorrhoeae to reduce the development of drug resistant bacteria and maintain the effectiveness of cefixime and other antibacterial drugs cefixime for oral suspension and cefixime capsule should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antimicrobial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy http://purl.org/np/RAo2_Vl7BPtEMnusRlyv7yq5u48JfxgHZdFwWHFxLtJr4#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RAo2_Vl7BPtEMnusRlyv7yq5u48JfxgHZdFwWHFxLtJr4#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RAo2_Vl7BPtEMnusRlyv7yq5u48JfxgHZdFwWHFxLtJr4#association https://w3id.org/biolink/vocab/relation https://schema.org/TreatmentIndication https://identifiers.org/drugbank:DB00671 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RAo2_Vl7BPtEMnusRlyv7yq5u48JfxgHZdFwWHFxLtJr4#provenance http://purl.org/np/RAo2_Vl7BPtEMnusRlyv7yq5u48JfxgHZdFwWHFxLtJr4#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAo2_Vl7BPtEMnusRlyv7yq5u48JfxgHZdFwWHFxLtJr4#pubinfo http://purl.org/np/RAo2_Vl7BPtEMnusRlyv7yq5u48JfxgHZdFwWHFxLtJr4#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RAo2_Vl7BPtEMnusRlyv7yq5u48JfxgHZdFwWHFxLtJr4#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RAo2_Vl7BPtEMnusRlyv7yq5u48JfxgHZdFwWHFxLtJr4#sig http://purl.org/nanopub/x/hasSignature I06YAwuMfxTTta0kogL+Wkj10NH1Qi3KibPkR7WeE/3Rz/uv+FFNLAbWGIS+ewYcbbX95/BZoNr+mybxwJ8bslBH2Xvq0QM1lwF20+CE98rbCIOpYxGKiZ1Ou/dHURN/cwhc8UDpX6oZvNEsLhTmMknPJij+lXsXdFmkyjuwwag= http://purl.org/np/RAo2_Vl7BPtEMnusRlyv7yq5u48JfxgHZdFwWHFxLtJr4#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RAo2_Vl7BPtEMnusRlyv7yq5u48JfxgHZdFwWHFxLtJr4 http://purl.org/np/RAo2_Vl7BPtEMnusRlyv7yq5u48JfxgHZdFwWHFxLtJr4 http://purl.org/dc/terms/created 2021-06-27T20:58:59.400+02:00 http://purl.org/np/RAo2_Vl7BPtEMnusRlyv7yq5u48JfxgHZdFwWHFxLtJr4 http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAo2_Vl7BPtEMnusRlyv7yq5u48JfxgHZdFwWHFxLtJr4 https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RAo2_Vl7BPtEMnusRlyv7yq5u48JfxgHZdFwWHFxLtJr4 https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RAo2_Vl7BPtEMnusRlyv7yq5u48JfxgHZdFwWHFxLtJr4 https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs